Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Massimo Napolitano

Vascular Surgery Wayne, NJ Medical Doctor

NPI 1316007743 CMS profile 104251

504 Valley Road, Suite 203, Wayne, NJ 07470

Open in the dashboard

General payments

$147,408

129 records reported · program years 2019–2025

Research payments

$6,517

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Massimo Napolitano of Wayne, NJ is reported in the CMS Open Payments database as having received $147,408 across 129 general payments and $6,517 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,728 28
2024 General $8,711 5
2023 General $15,457 9
2022 General $41,573 26
2021 General $32,525 24
2020 General $5,483 8
2020 Research $5,985 1
2019 General $16,931 29
2019 Research $532 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Massimo Napolitano
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Massimo Napolitano were reported at $26,728. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Massimo Napolitano Vascular Surgery median Middle half National median
2019 $16,931 $796 $226–$2,363 $163
2020 $5,483 $348 $118–$1,110 $114
2021 $32,525 $471 $158–$1,421 $132
2022 $41,573 $725 $222–$2,183 $149
2023 $15,457 $836 $257–$2,440 $160
2024 $8,711 $909 $252–$2,619 $164
2025 $26,728 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CVRx, Inc. $103,376 66 payments
  2. Globus Medical, Inc. $26,267 22 payments
  3. NuVasive, Inc. $16,436 19 payments
  4. Medtronic Vascular, Inc. $400 8 payments
  5. Stryker Corporation $325 2 payments
  6. Alphatec Spine, Inc $142 1 payment
  7. Checkpoint Surgical, Inc $96 1 payment
  8. W. L. Gore & Associates, Inc. $87 1 payment
  9. Medtronic, Inc. $70 1 payment
  10. Cook Medical LLC $48 1 payment
  11. Other $160 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $128,125 33 payments
  2. Travel and Lodging $10,506 31 payments
  3. Food and Beverage $4,777 64 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,000 1 payment
Products named General payments · program years 2019–2025
  1. Barostim Neo System $103,376 66 payments
  2. ALIF Spine/Spine Surgery $22,249 18 payments
  3. ALIF Spine/Spine Surgery $12,072 13 payments
  4. XLIF $4,077 3 payments
  5. EXCELSIUS GPS $3,850 2 payments
  6. Hedron $260 2 payments
  7. Endurant $179 4 payments
  8. MONTEREY AL $175 1 payment
  9. Valiant Captivia $155 2 payments
  10. CASCADIA INTERBODY SYSTEM $150 1 payment
  11. Other $973 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Integra LifeSciences Corporation $6,517 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

24

Median for Vascular Surgery: 122

Drug cost

$107

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 24 $107

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$3,374

Medicare's payments for the services billed

Medicare patients

12

Average age 75

Services billed

15

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record